肠道菌群对化疗药物抗肿瘤疗效的影响及其研究进展

Progress of Gut Microbiota in the Antineoplastic Efficacy of Chemotherapeutic Drugs

药物化疗依然是目前癌症最基础的治疗方法之一,然而不同患者对化疗药物的敏感性存在个体间的差异,有些甚至对药物化疗产生耐药,此类问题成为肿瘤临床治疗过程中的棘手问题。近年研究显示,肠道菌群可以通过多种机制调节宿主对化疗的反应,包括免疫相互作用、异质代谢和改变菌落结构,对新近兴起的免疫治疗及化疗药物的疗效发挥关键性的调节作用。笔者介绍临床上使用的传统化疗药物以及新型免疫治疗药物抗CTLA-4以及抗PD-1抗体对肠道菌群的影响,以及此种作用对化疗疗效的影响及其作用机制,以期为以肠道菌群为潜在靶点的癌症治疗提供依据和线索。

Chemotherapeutic drugs play an important role in the treatment of cancer,but the individual differences of patients'sensitivity to chemotherapeutic drugs and the drug resistance of chemotherapeutic drugs have always been a thorny problem in clinical treatment.Recent studies have shown that gut microbiota plays a key role in regulating the efficacy of chemotherapeutic drugs.Gut microbiota can regulate host response to chemotherapy through a variety of mechanisms,including immune interaction,heterogeneous metabolism and changes in community structure.This paper introduces the effects of traditional chemotherapeutic drugs and new immunotherapeutic drugs,such as anti-CTLA-4 and anti-PD-1 antibodies,on gut microbiota,as well as their effects on chemotherapeutic efficacy and mechanism,in order to provide evidences and clues for cancer treatments targeting gut microbiota.